Table 2 Treatment summary

From: The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

  

No. of cycles

  

Docetaxel

Figitumumab

Dose of figitumumab (mg kg–1)

n

Median

Range

Median

Range

0.1

3

6

3–8

10

3–13

0.4

3

6

5–8

10

5–10

0.8

3

4

3–13

10

4–14

1.5

3

3

2–12

3

2–17

3

3

6

2–10

8

2–12

6

3

7

2–8

7

2–8

10

9

4

2–10

4

2–10

20

19

4

1–10

4

1–21

  1. Docetaxel was dosed at 75 mg m–2.
Back to article page